Importer of Controlled Substances; Notice of Application, 64298 [E6-18431]

Download as PDF 64298 Federal Register / Vol. 71, No. 211 / Wednesday, November 1, 2006 / Notices Any questions may be directed to the Joint Board’s Executive Director at 202– 622–8229. The deadline for accepting applications is December 15, 2006. Dated: October 11, 2006. Patrick W. McDonough, Executive Director, Joint Board for the Enrollment of Actuaries. [FR Doc. 06–8992 Filed 10–31–06; 8:45 am] BILLING CODE 4830–01–P DEPARTMENT OF JUSTICE Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: October 25, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–18431 Filed 10–31–06; 8:45 am] Dated: October 25, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–18376 Filed 10–31–06; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application BILLING CODE 4410–09–P Drug Enforcement Administration sroberts on PROD1PC70 with NOTICES Importer of Controlled Substances; Notice of Application DEPARTMENT OF JUSTICE Prior to issuing a registration under 21 U.S.C. 952(a)(2)(B), and in accordance with 21 CFR 1301.34(a), this is notice that on July 25, 2006, Alcan PackagingBethlehem, 2400 Baglyos Circle, Bethlehem, Pennsylvania, 18020, has made application to the Drug Enforcement Administration (DEA) to be registered as an importer of Nabilone (7379), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance for packaging and for distribution. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than December 1, 2006. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substance listed in schedule I or II are, and will continue to be, required to demonstrate to the VerDate Aug<31>2005 17:36 Oct 31, 2006 Jkt 211001 Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By notice dated July 25, 2006, and published in the Federal Register on July 31, 2006, (71 FR 43210), Aptuit, 10245 Hickman Mills Drive, Kansas City, Missouri 64137, made application by letter to the Drug Enforcement Administration (DEA) to be registered as an importer of Marihuana (7360), a basic class of controlled substance listed in schedule I. The company plans to import a finished pharmaceutical product containing cannabis extracts in dosage form for packaging for a clinical trial study. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Aptuit to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Aptuit to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 28, 2006, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Sufentanil (9740), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substance in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than January 2, 2007. Dated: October 25, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–18375 Filed 10–31–06; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By notice dated July 26, 2006, and published in the Federal Register on August 1, 2006, (71 FR 43526), Kenco VPI, Division of Kenco Group Inc., 350 E:\FR\FM\01NON1.SGM 01NON1

Agencies

[Federal Register Volume 71, Number 211 (Wednesday, November 1, 2006)]
[Notices]
[Page 64298]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-18431]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Prior to issuing a registration under 21 U.S.C. 952(a)(2)(B), and 
in accordance with 21 CFR 1301.34(a), this is notice that on July 25, 
2006, Alcan Packaging-Bethlehem, 2400 Baglyos Circle, Bethlehem, 
Pennsylvania, 18020, has made application to the Drug Enforcement 
Administration (DEA) to be registered as an importer of Nabilone 
(7379), a basic class of controlled substance listed in schedule II.
    The company plans to import the listed controlled substance for 
packaging and for distribution.
    Any manufacturer who is presently, or is applying to be, registered 
with DEA to manufacture such basic class of controlled substance may 
file comments or objections to the issuance of the proposed 
registration and may, at the same time, file a written request for a 
hearing on such application pursuant to 21 CFR 1301.43 and in such form 
as prescribed by 21 CFR 1316.47.
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than December 1, 2006.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-46), all applicants for 
registration to import a basic class of any controlled substance listed 
in schedule I or II are, and will continue to be, required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: October 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E6-18431 Filed 10-31-06; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.